E-DRUG: WHO Assessment tool for measuring transparency
in the public pharmaceutical sector
-----------------------------------------------
WHO announces the publication of its "Assessment tool for Measuring
Transparency in the Public Pharmaceutical sector"
http://www.who.int/medicines/areas/policy/goodgovernance/AssessmentInstr
umentMeastranspENG.PDF
The tool represents the first step of a three-phase approach within The
Good Governance for Medicines (GGM) programme started in late 2004, in
line with the WHO Global Medicines Strategy 2004-2007. The GGM programme
goal is to contribute to the health systems strengthening and prevent
corruption by promoting good governance in the pharmaceutical sector.
The purpose of the national assessment is to provide countries with a
comprehensive picture of the level of transparency and potential
vulnerability to corruption of the following eight functions of the
pharmaceutical sector:
1. Registration of medicines
2. Control of medicines promotion
3. Inspection of establishments
4. Control of clinical trials
5. Licensing of establishments
6. Selection of essential medicines
7. Procurement of medicines
8. Distribution of medicines
The methodology probes the perception of pharmaceutical policy makers
and other stakeholders about transparency and provides both qualitative
and quantitative information on the level of transparency present in the
eight areas.
The assessment should be viewed as a starting point for investigating
weaknesses as well as strengths in the national medicine regulatory and
supply management systems. It represents the beginning of a process
aimed at bringing long-lasting changes through efforts to strengthen the
national health systems. The implementation of assessment's
recommendations will build a more transparent and accountable
pharmaceutical sector in the participating countries, improving
equitable access to good-quality and safe medicines.
26 countries have adopted the GGM and conducted the assessment. WHO,
with clearance from Ministries of Health has published 13 country
assessment findings:
Measuring transparency to improve good governance in the public
pharmaceutical sector
Full text [pdf 2.46Mb]
<http://www.who.int/entity/medicines/areas/policy/goodgovernance/Transpa
rency4CountryStudy.pdf>
Measuring transparency to improve good governance in the public
pharmaceutical sector; A comparative analysis of 5 country assessment
studies.
Full text
<http://www.who.int/entity/medicines/areas/policy/goodgovernance/5countr
y_analysis/en/index.html>
Measuring transparency to improve good governance in the public
pharmaceutical sector - Jordan
Full text
<http://www.who.int/entity/medicines/areas/policy/goodgovernance/measuri
ngtransparencyjordan/en/index.html>
Measuring transparency to improve good governance in the public
pharmaceutical sector in Malawi
Full text
<http://www.who.int/entity/medicines/areas/policy/goodgovernance/Measuri
ngTransparencyMalawi/en/index.html>
Measuring transparency to improve good governance in the public
pharmaceutical sector - Lebanon
Full text
<http://www.who.int/entity/medicines/areas/policy/goodgovernance/measuri
ngtransparencylebanon/en/index.html>
Measuring transparency to improve good governance in the public
pharmaceutical sector - Syrian Arab Republic
Full text
<http://www.who.int/entity/medicines/areas/policy/goodgovernance/measuri
ngtransparencysyria/en/index.html>
For more information you can visit the GGM website:
http://www.who.int/medicines/ggm/ or contact Dr. Guitelle
Baghdadi-Sabeti : Medicines Access and Rational Use, Department of
Essential Medicines and Pharmaceutical Policies.
E-mail: ggminfo@who.int
"Baghdadi-Sabeti, Guitelle" <baghdadig@who.int>